# A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

> **NCT01870739** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 115 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** sacubitril/valsartan (LCZ696)
- **DRUG:** olmesartan
- **OTHER:** placebo to sacubitril/valsartan (LCZ696)
- **OTHER:** placebo to olmesartan
- **DRUG:** Amlodipine (Optional)

## Key facts

- **NCT ID:** NCT01870739
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870739, "A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT01870739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*